Search

Sarcopenia is a prognostic factor for cancer. Because creatinine is formed from creatine phosphate in muscle tissue, urinary creatinine excretion (UCE) serves as an index of muscle volume. However, as of yet, there are no studies assessing the clinical impact of UCE or weight- adjusted urinary creatinine excretion (WA-UCE) on allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. We analyzed the association between pre-transplant WA-UCE and transplant outcomes among 164 adult patients with acute myeloid leukemia in complete remission who underwent their first allo-HSCT at our center. The patients were classified into a high (

Platelet-derived growth factor receptor (PDGFRβ) gene is located on chromosome 5q31-33; its rearrangement leads to constitutive tyrosine kinase activity [1]. Hematological malignancies associated w...

The World Health Organization (WHO) has categorized acute undifferentiated leukemia (AUL) as a rare subtype of acute leukemias of ambiguous lineage (ALAL). The prognosis of AUL is considered poor a...

Recent studies have shown that CD25 expression at the time of diagnosis of acute myeloid leukemia (AML) may be associated with an unfavorable outcome. We focus on patients with AML without complete remission (CR) and examine the clinical correlation between surface CD25 expression at the time of transplant and subsequent transplant outcomes. We observed a significant difference in overall survival (OS), disease-free survival (DFS) and cumulative incidence of relapse (CIR) between CD25 positive (+) (n = 22) and negative (-) groups (n = 44) (2-year OS; CD25 (+) group: 5% vs. CD25 (-) group: 40%, p

We retrospectively analyzed 2682 patients who developed grade II-IV acute graft-versus-host disease (GVHD). On analysis with stratification into five age groups (20-29, 30-39, 40-49, 50-59 and ≥60), 2-year non-relapse mortality rates (NRM) after the onset of GVHD were 20.7, 26.2, 26.6, 37.0 and 40.4%, respectively (p

(99%), CD5 (98%), CD7 (18%), CD4 /CD8 (76%), CD4 / CD8 (22%), CD19 (1%), CD20 (2%), CD11b (64%), CD33 (1%), CD13 (1%), human leukocyte antigen (HLA)-DR (18%), CD30 (13%) and terminal deoxynucleotidyl transferase (TdT) ( ). Th e atypical lymphocytes observed in the peripheral blood showed essentially the same immunophenotype as the BM, i.e. CD2 (93%), CD3 (99%), CD5 (98%), CD7 (19%), CD4 /CD8 (75%), CD4 /CD8 (23%), CD19 (0.6%), CD20 (0.5%), CD11b (64%), CD33 (0.7%), CD13 (0.4%), HLA-DR (15%) and CD30 (27%). No clonal immunoglobulin heavy chain was present, but TCR C β 1 rearrangement was detected

AA amyloidosis is a rare complication of chronic inflammatory conditions. In developing countries, the main causes of this disorder are chronic infections, whereas in Western countries, the main ca...

To examine whether serum levels of soluble interleukin-2 receptor (sIL-2R) may be a good marker of acute graft-versus-host disease (aGVHD), they were determined weekly in 56 patients receiving bone marrow transplantation (BMT). Because of wide variation in the pre-transplant sIL-2R levels (from 135 to 1918 IU/ml), we used a sIL-2R index in this study by comparing the peak levels with the pre-transplant levels. In agreement with previous reports, there was a significant correlation between the grade of aGVHD and the maximal sIL-2R index. The maximal sIL-2R index was 4.66 in patients with grade I to IV aGVHD, whereas it was 2.68 in patients without GVHD. This marker may be useful for monitoring the status of aGVHD. However, it was interesting that sIL-2R levels were elevated from the time of transplantation until the third week even in patients without GVHD or those who received autologous transplantation. Until the third week, no significant differences were observed in sIL-2R index between these patients and those who developed aGVHD during their clinical courses. After the fourth week, a higher sIL-2R index was observed in patients with aGVHD than in the other patients. Some factors other than GVHD contribute to the elevation of serum sIL-2R levels, and we should recognize the limitations of the measurement of this cytokine.